November 05, 2025

From Tissue to Treatment

Optimizing biomarker testing in prostate cancer

The Pathologist

October 29, 2025

Recent Advances in Treating Diffuse Large B-Cell Lymphoma

The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma and included both lymphomas...

The ASCO Post

October 28, 2025

What's in England's Cancer Plan?

And will it help to achieve earlier cancer diagnoses?

The Pathologist

October 24, 2025

Cracking Prostate Cancer’s Code: What the STAMPEDE Trial Reveals

Genomic classifiers offer pathologists a clearer picture of tumor aggressiveness and progression

The Pathologist

October 23, 2025

Pathology’s Precision Oncology Mandate

The expanding role of pathologists as stewards of precision medicine for bladder cancer

The Pathologist

October 20, 2025

Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer

The Dana-Farber-co-led phase 3 IMvigor011 trial results show that periodic ctDNA screening after surgery can help guide a decision to begin adjuvant immunotherapy.

Dana-Farber

October 17, 2025

Where Renal Cancer Strikes Hardest – and Why the Numbers Are Climbing Fast

Global analysis reveals sharp rises in incidence, survival gaps across regions, and key genetic risk factors shaping diagnostics

The Pathologist

October 14, 2025

LDTs: The Hidden Engines of Precision Medicine

How LDTs give labs the agility to innovate beyond red tape – and deliver critical answers when patients need them most

The Pathologist

October 10, 2025

Seaport Criteria Bring Clarity to Myocarditis Grading

New guidelines combine hematoxylin and eosin and CD3 staining to improve diagnostic accuracy and reproducibility worldwide

The Pathologist